Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials

AIM: To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. METHODS: Safety data from 14 trials (8–104‐week durations) were analysed by treatment (alirocumab or placebo/ezetimibe control) and diabetes status (ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, L. A., Tinahones, F. J., Karalis, D. G., Bujas‐Bobanovic, M., Letierce, A., Mandel, J., Samuel, R., Jones, P. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585811/
https://www.ncbi.nlm.nih.gov/pubmed/30183102
http://dx.doi.org/10.1111/dme.13817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585811/
https://www.ncbi.nlm.nih.gov/pubmed/30183102
http://dx.doi.org/10.1111/dme.13817

Ejemplares similares